[
  {
    "ts": null,
    "headline": "Assessing Henry Schein (HSIC) Valuation After Recent Share Price Decline",
    "summary": "Henry Schein (HSIC) stock has seen a decline of nearly 12% over the past year, causing some investors to take a closer look. This underperformance is prompting fresh discussions about its valuation and growth prospects. See our latest analysis for Henry Schein. Henry Schein’s share price has steadily faded this year, with a 30-day share price return of -8.08% and a one-year total shareholder return of -11.9%. This reflects lingering uncertainty around its growth prospects and shifts in...",
    "url": "https://finnhub.io/api/news?id=1b1f5650bc629b1510f29060df71ec7719fc894dc7d70682e350d367a197c2a9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760649117,
      "headline": "Assessing Henry Schein (HSIC) Valuation After Recent Share Price Decline",
      "id": 137122758,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "HSIC",
      "source": "Yahoo",
      "summary": "Henry Schein (HSIC) stock has seen a decline of nearly 12% over the past year, causing some investors to take a closer look. This underperformance is prompting fresh discussions about its valuation and growth prospects. See our latest analysis for Henry Schein. Henry Schein’s share price has steadily faded this year, with a 30-day share price return of -8.08% and a one-year total shareholder return of -11.9%. This reflects lingering uncertainty around its growth prospects and shifts in...",
      "url": "https://finnhub.io/api/news?id=1b1f5650bc629b1510f29060df71ec7719fc894dc7d70682e350d367a197c2a9"
    }
  },
  {
    "ts": null,
    "headline": "Henry Schein and Biomerica Enter into Marketing Services Agreement for Biomerica’s inFoods® IBS Test in the U.S.",
    "summary": "- Expands Marketing of Non-Drug IBS Symptom Management Test Through One of the Nation’s Most Trusted Health Care Distributors- Relationship Marks a Key Milestone in Biomerica’s Commercialization Strategy IRVINE, Calif., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global biomedical company, announced today a marketing services arrangement with Henry Schein, Inc. (Nasdaq: HSIC), the world’s largest provider of health care solutions to office-based dental and medical practit",
    "url": "https://finnhub.io/api/news?id=36ff220f05cde994c96c9feb342e2cdbf107f708885f7d3d6bdf5a5642838851",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760617140,
      "headline": "Henry Schein and Biomerica Enter into Marketing Services Agreement for Biomerica’s inFoods® IBS Test in the U.S.",
      "id": 137104978,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "HSIC",
      "source": "Yahoo",
      "summary": "- Expands Marketing of Non-Drug IBS Symptom Management Test Through One of the Nation’s Most Trusted Health Care Distributors- Relationship Marks a Key Milestone in Biomerica’s Commercialization Strategy IRVINE, Calif., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global biomedical company, announced today a marketing services arrangement with Henry Schein, Inc. (Nasdaq: HSIC), the world’s largest provider of health care solutions to office-based dental and medical practit",
      "url": "https://finnhub.io/api/news?id=36ff220f05cde994c96c9feb342e2cdbf107f708885f7d3d6bdf5a5642838851"
    }
  }
]